May 09, 2023 / 03:55PM GMT
Jason Zemansky - Bank of America and BofA Securities - Analyst
If everyone can take their seats. I'm very (multiple speakers) okay, should be on. Perfect. Well, good morning, everyone. My name is Jason Zemansky and the new SMid-Cap Biotech Analyst here at BofA. and I'm very pleased this morning to be able to introduce Kevin Koch at Edgewise. Good morning.
Kevin Koch - Edgewise Therapeutics - President, CEO, & Member of Board of Directors
Hi! How are you doing?
Questions and Answers:
Jason Zemansky - Bank of America and BofA Securities - AnalystPerfect. Well, maybe to start more broadly, can you remind us your lead program 5506? How does it work? And how does it impact muscle damage?
Kevin Koch - Edgewise Therapeutics - President, CEO, & Member of Board of Directors
Yes. So (technical difficulty) a little bit lower. Okay, so how it affects muscle damage? So during in Duchenne and Becker muscular dystrophy, they're missing a key structural protein called